Retatrutide

GLP3-R

Price range: $175.00 through $295.00

GLP3-R (Reta) is an innovative triple-action research peptide that represents the cutting edge of metabolic health investigation. This synthetic compound activates three different hormone receptors (GLP-1, GIP, and glucagon), making it a unique tool for researchers studying weight management, glucose metabolism, and energy balance. Unlike traditional single or dual-action peptides, GLP3-R’s triple-receptor approach offers scientists an unprecedented opportunity to explore comprehensive metabolic pathways in laboratory settings.

This lyophilized powder requires reconstitution with bacteriostatic water before use in research applications. GLP3-R has shown remarkable potential in preclinical studies, demonstrating significant effects on weight reduction and metabolic markers. This product is exclusively for laboratory research and not for human or animal use.

Overview

Imagine your body’s metabolism as a complex orchestra, with different hormones playing various instruments to create the symphony of energy balance. GLP3-R acts like a master conductor who can direct three different sections of this orchestra simultaneously – the GLP-1, GIP, and glucagon sections – creating a more harmonious and powerful metabolic response than any single hormone could achieve alone.

GLP3-R represents a groundbreaking advancement in peptide research, offering scientists a unique triple-receptor agonist that targets multiple metabolic pathways simultaneously. This synthetic peptide has captured the attention of researchers worldwide due to its unprecedented ability to activate three critical hormone receptors involved in weight management and glucose control.

This product is strictly for research purposes only. Not approved for human or animal use.

Key Characteristics

MOLECULAR PROFILE

Formula: C221H342N46O68

Weight: 4191.7 g/mol

CAS: 2381089-83-2

Targets: GLP-1, GIP, Glucagon receptors

PHYSICAL PROPERTIES

Form: Lyophilized powder (white to off-white)

Solubility: Water-soluble

Storage: Keep refrigerated 36‑46 °F (2‑8 °C)

Reconstitution: Mix with bacteriostatic water

How It Works

GLP3-R works by simultaneously activating three important hormone receptors: GLP-1, GIP, and glucagon receptors, creating a comprehensive metabolic response that surpasses single-pathway approaches.

Triple-Receptor Activation

GLP-1 Receptor

Triggers insulin release when blood sugar is high, slows stomach emptying, and reduces appetite signals.

GIP Receptor

Enhances insulin response and influences fat metabolism pathways for improved metabolic efficiency.

Metabolic Benefits

Glucagon Receptor

Helps the body burn stored fat for energy and maintains healthy blood sugar levels between meals.

Synergistic Effect

The triple-action approach creates a comprehensive metabolic response more effective than single-pathway targeting.

Research Findings

Preclinical research has demonstrated GLP3-R’s remarkable potential across multiple metabolic research domains, showing superior outcomes compared to single-receptor approaches.

Weight Management Studies

Preclinical research has demonstrated significant weight reduction in laboratory models with dose-dependent effects and synergistic triple-receptor mechanisms.

Significant weight reduction in laboratory models
Dose-dependent effects with higher doses showing greater outcomes
Synergistic effects surpassing single or dual-receptor agonists
Sustained weight management over extended periods

Metabolic Health Research

Laboratory investigations have revealed comprehensive improvements across multiple metabolic markers and pathways in research models.

Enhanced glucose homeostasis and insulin sensitivity
Improved lipid profiles in research models
Reduced inflammatory markers
Better energy expenditure patterns

Comparative Studies

When compared to other GLP-1 receptor agonists, GLP3-R has demonstrated superior outcomes in weight reduction and metabolic improvements.

Superior weight reduction compared to single-receptor compounds
Enhanced metabolic improvements beyond GLP-1 alone
Addition of GIP and glucagon activation provides unique benefits
Improved therapeutic potential in research settings

Clinical Translation Research

Phase 2 trials have shown promising results for obesity and type 2 diabetes applications with significant clinical improvements.

Phase 2 trial results showing substantial weight loss
Improved glycemic control in diabetes research
Cardiovascular and metabolic benefits
Potential for transforming metabolic disorder treatment

Potential Side Effects in Research

During preclinical studies, researchers have observed several potential side effects that should be carefully monitored in laboratory settings.

Gastrointestinal Effects

Mild nausea, reduced appetite, and slower gastric emptying have been noted in research models during administration.

Injection Site Reactions

Some research subjects showed minor irritation at administration sites, typically mild and transient.

Blood Sugar Considerations

While rare, hypoglycemia has been observed, particularly when combined with other glucose-lowering agents.

Cardiovascular Observations

Slight increases in heart rate have been documented in some studies, requiring careful monitoring.

Researchers should maintain detailed records of any observed effects and follow appropriate safety protocols during investigations.

IMPORTANT: This product is exclusively for laboratory research purposes and is not approved for human or veterinary use.

References

  1. Jastreboff, A. M., et al. (2023). “Triple-Hormone-Receptor Agonist GLP3-R for Obesity — A Phase 2 Trial.” New England Journal of Medicine, 389, 514-526.
  2. Rosenstock, J., et al. (2023). “GLP3-R, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial.” The Lancet, 402(10401), 529-544.
  3. Urva, S., et al. (2023). “GIP, GLP-1, and Glucagon Receptor Agonist GLP3-R Improves Glycemic Control and Reduces Body Weight in Patients with Type 2 Diabetes.” Diabetes, 72(Supplement_1).
  4. Coskun, T., et al. (2023). “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.” Nature Medicine, 29, 2300-2312.
  5. Wang L, et al. (2024). “Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis.” Diabetes Obes Metab, 26(12), 5521-5533.

Third-Party Lab Tested

View our independent laboratory test certificate showing purity and composition analysis.


📋 View Test Certificate →

Weight N/A
Dimensions N/A
Size

12mg, 24mg
SKU: OATH-RETATRUTIDE Category: Tags: , ,
Lab Tested and Shipped from the USA
Free Bacteriostatic Water
Free Shipping on Orders Over $200
The Purest Peptides. Period.
Updating…
Cart Close
  • No products in the cart.

Continue shopping